Subjects with topical and/or systemic medication or mechanical devices that interfere determinedly on the results of the study (such as topical immunomodulators, punctal plugs, corticosteroids, preservative artificial tears, contact lenses).
Subjects (females) with active sexual life that do not use a contraceptive method.
Female subjects who are pregnant or lactating
Female subjects with a positive urine pregnancy test
Positive drug addictions* (verbal interrogatory)
Subjects who have participated on any other research clinical trials on the last 40 days
Subjects legal or mentally disabled to give an informed consent for participating on this study
Subjects who can't comply with the appointments or with every protocol requirement.
Serious tear film dysfunction syndrome TBUT < 5 s Schirmer: < 4 mm OSDI > 30 pints Corneal staining > grade III on the Oxford scale
Non perforated corneal ulcer
Perforated corneal ulcer
Autoimmune corneal ulcer
Ocular surface scarring diseases
Ocular surface or annexes metaplastic lesions
Fibro vascular proliferation lesions on the conjunctival and/or corneal surface (i.e.: pterygium)
Concomitant chronic inflammatory diseases on any ocular structure
Acute or infectious inflammatory disease
Corneal disease potentially requiring a treatment during the following 3 months
Use of topical or systemic drug products classified as forbidden
Ocular surgical procedures 3 months before the protocol inclusion
Treatments or procedures indicated on the tear film dysfunction treatment, as punctal silicone plugs.
Posterior segment diseases requiring a treatment or threatening the visual prognosis
Retinal diseases potentially requiring treatment during the following 3 months
History of penetrating keratoplasty.
Soft or hard contact lenses use during the last month from inclusion day

NCT03223909_exc_T1
Drug
systemic medication
NCT03223909_exc_T2
Drug
topical medication
NCT03223909_exc_T3
Device
mechanical devices
NCT03223909_exc_T4
Drug
topical immunomodulators
NCT03223909_exc_T5
Device
punctal plugs
NCT03223909_exc_T6
Drug
corticosteroids
NCT03223909_exc_T7
Drug
preservative artificial tears
NCT03223909_exc_T8
Device
contact lenses
NCT03223909_exc_T9
Scope
topical immunomodulators, punctal plugs, corticosteroids, preservative artificial tears, contact lenses
NCT03223909_exc_T10
Scope
topical and/or systemic medication or mechanical devices
NCT03223909_exc_T11
Person
females
NCT03223909_exc_T12
Observation
active sexual life
NCT03223909_exc_T13
Negation
not
NCT03223909_exc_T14
Procedure
contraceptive method
NCT03223909_exc_T15
Person
Female
NCT03223909_exc_T16
Condition
pregnant
NCT03223909_exc_T17
Condition
lactating
NCT03223909_exc_T18
Person
Female
NCT03223909_exc_T19
Value
positive
NCT03223909_exc_T20
Measurement
urine pregnancy test
NCT03223909_exc_T21
Condition
Positive drug addictions
NCT03223909_exc_T22
Procedure
verbal interrogatory
NCT03223909_exc_T24
Condition
mentally disabled
NCT03223909_exc_T25
Condition
or me ed to gi
NCT03223909_exc_T28
Condition
Serious tear film dysfunction syndrome
NCT03223909_exc_T29
Measurement
TBUT
NCT03223909_exc_T31
Value
< 5 s
NCT03223909_exc_T32
Measurement
Schirmer
NCT03223909_exc_T33
Value
< 4 mm
NCT03223909_exc_T34
Measurement
OSDI
NCT03223909_exc_T35
Value
> 30 pints
NCT03223909_exc_T36
Measurement
Corneal staining
NCT03223909_exc_T37
Value
> grade III
NCT03223909_exc_T38
Qualifier
Oxford scale
NCT03223909_exc_T43
Qualifier
Non perforated
NCT03223909_exc_T44
Condition
corneal ulcer
NCT03223909_exc_T45
Condition
corneal ulcer
NCT03223909_exc_T46
Qualifier
Perforated
NCT03223909_exc_T47
Condition
corneal ulcer
NCT03223909_exc_T48
Qualifier
Autoimmune
NCT03223909_exc_T49
Condition
Ocular surface scarring diseases
NCT03223909_exc_T50
Condition
 vascu e or annexes m
NCT03223909_exc_T51
Condition
lastic lesions
Fibro vascul e or a
NCT03223909_exc_T52
Condition
Fibro vascular proliferation lesions
NCT03223909_exc_T53
Qualifier
corneal surface
NCT03223909_exc_T54
Qualifier
conjunctival
NCT03223909_exc_T55
Qualifier
pterygium
NCT03223909_exc_T56
Scope
conjunctival and/or corneal surface
NCT03223909_exc_T57
Temporal
Concomitant
NCT03223909_exc_T58
Condition
chronic inflammatory diseases
NCT03223909_exc_T59
Qualifier
ocular structure
NCT03223909_exc_T60
Condition
inflammatory disease
NCT03223909_exc_T61
Qualifier
Acute
NCT03223909_exc_T62
Qualifier
infectious
NCT03223909_exc_T63
Scope
Acute or infectious
NCT03223909_exc_T64
Condition
Corneal disease
NCT03223909_exc_T65
Procedure
treatment
NCT03223909_exc_T66
Mood
potentially requiring
NCT03223909_exc_T67
Temporal
during the following 3 months
NCT03223909_exc_T69
Procedure
Ocular surgical procedures
NCT03223909_exc_T70
Temporal
3 months before the protocol inclusion
NCT03223909_exc_T71
Reference_point
protocol inclusion
NCT03223909_exc_T72
Temporal
3 months before the protocol inclusion
NCT03223909_exc_T73
Procedure
Treatments
NCT03223909_exc_T74
Procedure
procedures
NCT03223909_exc_T75
Procedure
tear film dysfunction treatment
NCT03223909_exc_T76
Device
punctal silicone plugs
NCT03223909_exc_T77
Scope
Treatments or procedures
NCT03223909_exc_T78
Condition
Posterior segment diseases
NCT03223909_exc_T79
Procedure
treatment
NCT03223909_exc_T80
Condition
threatening the visual prognosis
NCT03223909_exc_T81
Mood
requiring
NCT03223909_exc_T82
Scope
requiring a treatment or threatening the visual prognosis
NCT03223909_exc_T83
Device
hard contact lenses
NCT03223909_exc_T84
Procedure
penetrating keratoplasty
NCT03223909_exc_T85
Temporal
during the following 3 months
NCT03223909_exc_T86
Procedure
treatment
NCT03223909_exc_T87
Mood
requiring
NCT03223909_exc_T88
Condition
Retinal diseases
NCT03223909_exc_T89
Observation
History
NCT03223909_exc_T90
Device
ses g the last mon
NCT03223909_exc_T91
Temporal
during the last month from inclusion day
NCT03223909_exc_T92
Reference_point
inclusion day
NCT03223909_exc_T93
Scope
Soft or hard contact lenses